BriaCell Adds Next-Gen Ovarian Cancer Immunotherapy Bria-OVA+ After Phase 2 Breast Success
BCTX•BriaCell has expanded its pipeline to include Bria-OVA+, a next-generation personalized immunotherapy candidate for ovarian cancer designed with additional immune-stimulating components. The company has licensed ovarian cancer cell lines and commenced development following encouraging Phase 2 efficacy and tolerability results in advanced metastatic breast cancer.
1. Pipeline Expansion with Bria-OVA+
BriaCell has expanded its clinical pipeline to include Bria-OVA+, marking its entry into ovarian cancer immunotherapy and leveraging its recent Phase 2 breast cancer achievements.
2. Bria-OVA+ Design and Development
Bria-OVA+ is a personalized, cell-based immunotherapy enhanced with additional immune-stimulating components; BriaCell has licensed ovarian cancer cell lines from ATCC and initiated production activities for potential clinical use.
3. Ovarian Cancer Market Need
Ovarian cancer is the deadliest gynecologic malignancy in the U.S., with an estimated 21,010 diagnoses and 12,450 deaths projected in 2026, and current therapies leave many patients without effective options.
4. Bria-OTS+ Platform and Preclinical Success
BriaCell’s Bria-OTS+ platform has demonstrated activation of adaptive and innate immunity in the Bria-BRES+ preclinical candidate and delivered encouraging safety and efficacy results in its Phase 2 metastatic breast cancer study.
